Renal Cell Carcinoma-Antigen G250-derived Peptides that elicit both CD4+ and CD8+T-cell Responses

Details for Australian Patent Application No. 2002300986 (hide)

Owner Katholieke Universiteit Nijmegen

Inventors Adema, Gosse Jam; Figdor, Carl Gustav; Oosterwijk, Egbert; De Vries, Ingrid Jolanda Monique; Vissers, Joost Lambert Max

Agent A.P.T. Patent and Trade Mark Attorneys

Pub. Number AU-A-2002300986

Filing date 12 September 2002

Wipo publication date 1 April 2004

International Classifications

C07K 007/08 Peptides having 5 to 20 amino acids in a fully defined sequence

A61P 035/00 Antineoplastic agents

A61K 038/04 Medicinal preparations containing peptides - Peptides having up to 20 amino acids in a fully defined sequence

Event Publications

1 April 2004 Application Open to Public Inspection

  Published as AU-A-2002300986

13 September 2007 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(a). A direction to request examination has been given for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2002300987-Bed Liner Retainer Apparatus for Pickup Truck

2002300985-Imidazonaphthyridines And Their Use In Inducing Cytokine Biosynthesis